Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07494084 · ClinicalTrials.gov registry record · Phase 4

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

A Phase 4 study, sponsored by Washington State University.

Not yet
Registry status
Phase 4
Development phase
48
Enrollment target

NCT07494084: Clinical Trial Phase 4 study, sponsored by Washington State University.

NCT07494084 is a Phase 4 study that has not yet begun recruiting, run by Washington State University. The registered enrollment target is 48 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07494084, a Phase 4 study, has not yet begun recruiting, sponsored by Washington State University.

NOT YET RECRUITING
Registry status
Phase 4
Development phase
48 participants
Enrollment target

Study Summary

The purpose of this study is to examine the impact of timed cortisol release or differently timed cortisol rhythms on insulin resistance in both men and women undergoing sleep restriction. Chronic sleep loss is highly prevalent, affecting 1 in 3 adults in the US. Chronic sleep loss causes stress which induces insulin resistance and leads to obesity and type 2 diabetes. Many factors contribute to sleep loss including shift work, environmental disturbances, sleep/circadian disorders and comorbid medical and mental health conditions. Sleep loss increases the stress hormone cortisol in the evening and decreases daytime testosterone. Examining these hormones in a controlled laboratory environment under different sleep schedules may help researchers find solutions for adults experiencing negative health consequences related to chronic sleep loss.

Primary Outcome

Insulin resistance-minimal model (Si) will be measured from the frequently sampled intravenous glucose tolerance test (FSIVGTT) and reflects glucose disposal rate during the insulin response. it will be calculated as the change from baseline (by subtraction).

Interventions

  • DRUG Dextrose
  • DRUG insulin
  • DRUG Metyrapone And Hydrocortisone

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2026-07-01
Est. Completion 2029-07
Phase Phase 4
Washington State University

64 total trials

What is known before NCT07494084 opens enrollment

NCT07494084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 3 interventions - of which Dextrose is the first listed.

NCT07494084 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07494084 about?

NCT07494084 is a clinical study titled "Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance". The purpose of this study is to examine the impact of timed cortisol release or differently timed cortisol rhythms on insulin resistance in both men and women undergoing sleep restriction. Chronic sleep loss is highly prevalent, affecting 1 in 3 adults in the US. Chronic sleep loss causes stress whi...

What is the current status of trial NCT07494084?

This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2026-07-01. Estimated completion is 2029-07.

What interventions are being tested in trial NCT07494084?

The interventions under investigation include: Dextrose (DRUG), insulin (DRUG), Metyrapone And Hydrocortisone (DRUG).

Who is sponsoring clinical trial NCT07494084?

This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07494084's enrollment target sits among peer trials

48 1331st of 2000 higher than 653 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07494084, the US trial registry maintained by the National Library of Medicine. NCT07494084 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.